Novo Nordisk Expands AI Partnership With Valo Health
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...
Investing.com – Denmark stocks were lower after the close on Tuesday, as losses in the Personal & Household Goods, Healthcare and Industrials sectors led shares lower. At the... Investing.com ...
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.
Novo Nordisk is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
1d
Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback